Climb Bio, Inc.
CLYM
$7.01
-$0.12-1.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.56M | 5.82M | 4.10M | 5.69M | 4.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.30M | 14.89M | 10.68M | 23.02M | 7.55M |
| Operating Income | -19.30M | -14.89M | -10.68M | -23.02M | -7.55M |
| Income Before Tax | -17.52M | -12.89M | -8.67M | -20.78M | -8.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.52M | -12.89M | -8.67M | -20.78M | -8.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.52M | -12.89M | -8.67M | -20.78M | -8.42M |
| EBIT | -19.30M | -14.89M | -10.68M | -23.02M | -7.55M |
| EBITDA | -19.27M | -14.86M | -10.66M | -- | -- |
| EPS Basic | -0.26 | -0.19 | -0.13 | -0.31 | -0.13 |
| Normalized Basic EPS | -0.16 | -0.12 | -0.08 | -0.20 | -0.05 |
| EPS Diluted | -0.26 | -0.19 | -0.13 | -0.31 | -0.13 |
| Normalized Diluted EPS | -0.16 | -0.12 | -0.08 | -0.20 | -0.05 |
| Average Basic Shares Outstanding | 67.37M | 68.00M | 67.59M | 67.46M | 64.74M |
| Average Diluted Shares Outstanding | 67.37M | 68.00M | 67.59M | 67.46M | 64.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |